PubMed
MK-677, an orally active growth hormone secretagogue: effects on body composition
Murphy et al., 1998
GH SecretagoguesResearch OnlyB
MK-677
Ibutamoren
Oral ghrelin receptor agonist used in GH-axis research.
Observational report only — live community data. Not medical advice. Does not recommend doses, protocols, or treatments.
- Studies cited
- 6
- Research grade
- B
- Experience
- 99
- Activity
- 76
Overall check-ins
Trackers & reports
Overview
About MK-677
Oral ghrelin receptor agonist used in GH-axis research.
- Category
- GH Secretagogues
- Regulatory status
- Research Only
- Also known as
- Ibutamoren
- Self-reports
- 24
Community
What 24 users report
24 community reports
Overall experience
From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Favorable 98% · Mixed 2% · Unfavorable overall 0%
Most reported benefits
Benefits users selected when logging a favorable or mixed check-in.
Sleep
135
Most logged side effects
Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Water retention
2
Fatigue
1
Self-reported dose per injection
Median bucket: 2+ mg · Most common: 2+ mg
Reports span 2 to ≥ 2 mg (open-ended top bucket)
2+ mg
135
Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.
Commonly stacked with
How repeat users are trending
Among repeat reporters, 91% said they felt similar to their last entry, 9% more positive, and 0% more negative.
Overall, repeat reporters leaned more positive than their previous entry.
Median gap between entries: 156 days · Based on 22 repeat reporters
Research
Cited research (5)
Source
PubMed
Two-year treatment with ibutamoren increases bone mineral density, body composition, and quality of life
Nass et al., 2008
ClinicalTrials.gov
Ibutamoren (MK-677) studies on ClinicalTrials.gov
ClinicalTrials.gov, 2024
PubMed
MK-677, an orally active growth hormone secretagogue, reverses diet-induced catabolism
Murphy et al., 1998
PubMed
Characterization of growth hormone secretagogue small molecule ibutamoren (MK-0677) and its possible metabolites in thoroughbred horses for doping control
Philip et al., 2022
Tools
Explore more
Explore
More ways to learn about MK-677 from observational PeptIQ data.
Related peptides
Help
Frequently asked
What do PeptIQ users report about MK-677?
This page summarizes 24 anonymized self-reports from PeptIQ users who track MK-677, including commonly reported effects and co-tracked peptides. These are observational patterns, not clinical outcomes.
How do side effects relate to overall experience for MK-677?
PeptIQ separates overall check-in ratings (favorable, mixed, or unfavorable) from logged side effects like nausea or fatigue. Users often report benefits and side effects in the same check-in — a high experience score does not mean zero side effects were noted.
What research is cited for MK-677?
5 sources are linked on this page, including PubMed articles, clinical trial registries, and FDA labels where applicable. Citations describe published research — not recommendations.
Is MK-677 safe to use?
This wiki does not assess safety or recommend use. MK-677 is listed as Research Only. Consult a licensed clinician for personal medical decisions.
What are the purported benefits and uses of MK-677?
Research, primarily in animal models, suggests MK-677 may have a wide range of therapeutic potentials due to its ability to promote angiogenesis (formation of new blood vessels), stimulate collagen synthesis, and modulate inflammatory responses.
SourceWhat is the legal status of MK-677?
MK-677 is not approved by the FDA for any human use. There is no legal basis for selling it as a drug, food, or dietary supplement in the United States. The FDA has classified MK-677 as a Category 2 bulk drug substance, which explicitly prohibits licensed compounding pharmacies from using it in compounded medications.
SourceWhat are the known or theoretical side effects and risks of MK-677?
The safety and effectiveness of MK-677 have not been thoroughly evaluated in humans through rigorous clinical trials. This lack of human data means that safe dosages, short-term side effects, and long-term health consequences are largely unknown.
SourceWhat is the current state of research on MK-677?
While there are over 200 published studies on MK-677, the vast majority are animal or in vitro (cell) studies. These preclinical studies consistently show positive results across various tissue types. However, there is a significant lack of comprehensive human clinical trial data.
Source